Results: Median age was 63 years (range 32-84). Combination chemotherapy was delivered in 85 cases (41%) and single agent in 123 cases (59%), respectively. One hundred and seventy-one patients (82%) received an anthracyclinecontaining regimen. Using RECIST, objective response was observed in 21 patients (12%), all treated with anthracyclines. Median progression-free survival (PFS) was 4.6 months [95% confidence interval (CI) 3.3-5.9]. On multivariate analysis, age and performance status (PS) were the sole factors significantly associated with poor PFS. Median overall survival (OS) was 15.2 months (95% CI 11.8 -18.7). On multivariate analysis, grade and PS were the sole factors significantly associated with OS.
introduction
Accounting for up to 25% of all sarcomas in adults [1] , liposarcoma (LPS) is the most common soft-tissue sarcoma (STS). LPSs can be divided into three categories on the basis of their cytogenetic characteristics: myxoid/round cell LPS, pleomorphic LPS and well-differentiated/dedifferentiated LPS (WDLPS/DDLPS). WDLPS/DDLPS are characterized by the consistent presence of supernumerary rings and/or giant rod chromosomes that contain amplified sequences of the region 12q14-15 [2] with an overexpression of MDM2, HMGA2 and CDK4 resulting in uncontrolled proliferation through combined effects on p53 and the cell cycle. This genetic feature is now considered essential in the pathological diagnosis of these tumors [3, 4] and allows to reclassify as DDLPS a large number of retroperitoneal malignant fibrous histiocytomas diagnosed in former series [5, 6] . Moreover, the better understanding of these specific molecular aberrations in WDLPS/DDLPS has recently leaded to the development of several promising targeted therapeutic agents.
WDLPS represents >40% of all diagnosed LPS and are subdivided in three main histological subtypes: adipocytic, sclerosing and inflammatory. The three main locations are the limbs (50%), the retroperitoneum (30%) and the paratesticular area (20%). Although these tumors do not metastasize, retroperitoneal and paratesticular ones are associated with a high risk of local recurrence (up to 90%) and a high a risk of dedifferentiation (up to 20%) [7, 8] , whereas these risks are lower for tumors located in the limbs [9] .
DDLPS are biphasic neoplasms occurring in the same age group as WDLPS, with one component being a WDLPS and the other a non-lipogenic sarcoma of variable histological grade. About 90% of DDLPS arise de novo, while 10% occur in recurrence. This histological subtype is found mostly in the retroperitoneum [8, 10] and has a more aggressive behavior than WDLPS with an estimated 5-year disease-specific survival of 44% versus 93% [11] . The local recurrence rate for retroperitoneal tumors can reach 80% and distant metastatic relapse is observed in up to 30% of cases [7, 12] .
Surgery is the cornerstone of the primary management of WDLPS/DDLPS. Resection with R0 margin status is an achievable goal for WDLPS/DDLPS located in the limbs but is more challenging for retroperitoneal tumors for obvious anatomical reasons. Therefore, retroperitoneal tumors are associated with a higher rate of recurrence.
Systemic therapy is the most suitable approach for patients with advanced/unresectable disease. However, there are only limited data regarding the role of systemic treatment in patients with advanced WDLPS/DDLPS [13] . Indeed, the interpretation of the literature is complicated by the fact that past studies considered LPS and even soft tissue sarcomas as a homogeneous tumor type despite their differences in sensitivity to systemic agents.
The aim of this multi-institutional retrospective study was to assess the role of chemotherapy in patients with advanced WDLPS/DDLPS and to identify predictive factors of outcome that may help clinicians to choose the more appropriate regimen for their patients.
patients and methods patients
This study was based on retrospectively retrieved data from medical records of patients with unresectable and/or metastatic WDLPS/DDLPS who were treated at 10 European institutions, members of the CONTICANET (CONnective TIssue CAncers NETwork of excellence) and at the Memorial Sloan-Kettering Cancer Center (New York, NY). These institutions are major referral centers for sarcomas and agreed to cooperate for this study. Inclusion criteria were age ‡18 years, histologically proven WDLPS/DDLPS, unresectable and/or metastatic disease and first-line systemic treatment with a cytotoxic agent started between 2000 and 2010. In all cases, the histological diagnosis was established according to the World Health Organization Classification of Tumours [1] by an expert pathologist. The histological grade was determined as previously described according to the FNCLCC grading system. According to this grading system, WDLPS were scored grade 1.
treatments and evaluation
Patients were treated at the discretion of their physician. The best response to treatment was evaluated according to RECIST [14] . The clinical benefit rate (CBR) was defined as the rate of complete or partial response or stable disease of at least 6 months duration. Routine follow-up was similar across all centers. Progression-free survival (PFS) was defined as the time from the start of treatment until disease progression, death or last patient contact. Overall survival (OS) was defined as the time from the start of treatment until death or last patient contact.
statistical analysis
The cut-off date for statistical analysis of baseline demographic data and clinical outcome was the 31 March 2011. Survival rates were estimated using the Kaplan-Meier method. Descriptive statistics were used to show the distribution of variables in the population. Differences between groups were evaluated by chi-square test or Fisher's exact test for categorical variables and Student's test for continuous variables. Prognostic factors were planned to be identified by univariate and multivariate analyses using a Cox regression model. Variables tested in univariate analysis included age, gender, primary tumor location, grade, number of metastatic sites, presence of visceral metastasis, performance status (PS), single agent versus combination therapy, anthracycline-containing regimen versus anthracycline-free regimen. Variables associated with PFS and OS with a P-value <0.05 in the univariate analysis were planned to be included in the multivariate analysis. Analyses were carried out using SPSS 18.0 statistical software (IPSS Inc., Chicago, IL). All statistical tests were two-sided, and P < 0.05 indicated statistical significance. results patients Two hundred and eight patients were included in this study. Their characteristics are described in Table 1 .
treatments Combination chemotherapy was delivered in 85 cases (41%) and single agent in 123 cases (59%), respectively. An anthracycline-containing regimen was received by 171 (82%) patients. Chemotherapy regimens are described in Table 2 .
response One hundred and sixty-seven patients were assessable for response. Using RECIST, 2 patients (1%) had complete response, 19 patients (11%) had partial response and 81 patients (48%) had stable disease. Progressive disease was observed in 65 (39%) patients. The objective response rate was significantly higher in patients treated with an anthracycline-containing regimen (15% versus 0%, P = 0.02) and in patients treated with combination chemotherapy (18% versus 7.5%, P = 0.04). No difference of objective response rate was seen between WDLPS and DDLPS (13% versus 12%, P = 0.9). The CBR was 46% and was not significantly different between patients treated with anthracycline-containing and anthracycline-free regimens (48% versus 35%, P = 0.3) but was significantly higher in patients treated with combination chemotherapy (56% versus 36%, P = 0.01).
progression-free survival
The median follow-up was 28 months (range 23-33). Median PFS was 4.6 months [95% confidence interval (CI) 3.3-5.9] (Figure 1) . The 3-month, 6-month and 1-year PFS rates were 59% (95% CI 52-65), 44% (95% CI 37-51) and 28% (95% CI 22-34), respectively. On univariate analysis, age, number of metastatic sites, presence of visceral metastasis, PS and type of chemotherapy were significantly associated with PFS (Table 3) . There was also a trend for a higher PFS in WDLPS in comparison to DDLPS: 8.7 months (95% CI 0-18) versus 4 months (95% CI 2.6-5.5); P = 0.05.On multivariate analysis, age and PS were the two sole factors independently associated with PFS (Table 4, Figure 1 ).
overall survival
At the time of analysis, 136 patients (65%) had died and 73 (35%) were still alive. The median OS for the entire cohort of patients was 15.2 months (95% CI 11.8-18.7). The 6-month, 1-year and 2-year OS rates were 75% (95% CI 73-78), 59% (95% CI 57-61) and 37% (95% CI 35-38), respectively. On univariate analysis, age, histological subtype, grade, number of metastatic sites, presence of visceral metastasis and PS were significantly associated with OS (Table 3) . On multivariate analysis, grade and PS were the two sole factors independently associated with OS (Table 4, Figure 2 ). After completion of first-line chemotherapy, 114 patients (95 patients in the anthracycline group, 19 patients in the non-anthracycline group) received at least one new line of chemotherapy. Several types of chemotherapy regimen were used. The proportions of patients receiving a second-line chemotherapy in the anthracycline group and in the non-anthracycline group were similar (55% versus 51%, P = 0.64). The median number of subsequent lines of chemotherapy delivered after first-line was 1 (range 0-8).
discussion
We report here the largest series of advanced WDLPS/DDLPS patients treated with chemotherapy. In our study, the treatment characteristics are dominated by a very large majority of anthracycline-containing regimen administered (82%). Doxorubicin was given as single agent in 44% of cases, in agreement with the current guidelines [15] .
Objective responses were only observed in patients treated with anthracycline. The overall objective response rate of 12% in our study was significantly lower than in other sarcoma subtypes, even in patients treated with combination chemotherapy. Indeed, previous studies focusing on the role of anthracycline-based chemotherapy in STS and including miscellaneous histological subtypes showed objective response rates ranging between 9% and 27% for doxorubicin as single agent and between 35% and 60% for combined regimens. Interestingly, in a large retrospective analysis of 1922 patients with STS treated with anthracycline-based chemotherapy, LPS was identified as a favorable predictive factor for response to chemotherapy [16] . This is probably related to the predominance of myxoid LPS in this group, which are known to be more chemotherapy sensitive [17] and underscore the limits of studies considering LPS as a unique subtype. Moreover, our results are in agreement with those of a previous retrospective study that included 32 patients with advanced WDLPS/DDLPS and showed an ORR of 11%, all CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; NS, not significant.
original articles
Annals of Oncology responders being DDLPS treated with doxorubicin-based regimen [13] . Noteworthy, combination chemotherapy was given in a high proportion of patients (41%). The most frequent combined regimen was the association of doxorubicin and ifosfamide (19%). Only very limited data regarding the sensitivity of WDLPS/DDLPS to ifosfamide are available. Jones et al. [13] found a higher response rate with the association doxorubicin/ ifosfamide than with doxorubicin as single agent, but the number of patients included in the analysis was small. Altogether, in our series, combined chemotherapy was associated with a higher objective response rate but did not improve OS. This confirms the results of previous reports showing the absence of superiority of combination chemotherapy over single agent chemotherapy with doxorubicin alone in terms of OS in the metastatic setting in STS [18] [19] [20] [21] [22] [23] . However, combination chemotherapy may be considered as a treatment of choice when a tumor response is felt to be able to improve the patient's symptoms [24] .
Despite a low objective response rate, the median OS of patients with advanced WDLPS/DDLPS (15 months) was comparable if even better with that of other sarcoma subtypes. LPS has been described as having a longer OS when compared with other advanced STS [16, 25, 26] . This may be related to the natural history of WDLPS/DDLPS characterized by a lower rate of visceral metastatic disease. On multivariate analysis, PS and grade were the two sole independent factors associated with OS. The prognostic value of these two variables for survival has already been demonstrated in STS [16, [26] [27] [28] . The better outcome of grade 1 tumors in our series reflects probably the more indolent natural history of WDLPS that do not metastasize and have a slower local progression. Their median survival is 28 months versus 14 months for grade 3 DDLPS. Interestingly, we have not observed significant difference in terms of objective response rate to the first-line chemotherapy or in terms of number of further lines of systemic treatment between WDLPS and DDLPS. These results suggest that due to their indolent course, some patients with advanced WDLPS may benefit from a strategy of active surveillance. However, further studies are needed to clarify this point. Strikingly, patients with PS of two or more had a median OS of only 2.7 compared with 18.7 months for those with good PS. Recently, PS of two or more was also identified as the most significant risk factor for early death (<3 months) in patients with advanced STS treated with first-line chemotherapy [29] . Considering the high risk of early death of patients with poor PS in our series, the decision to administer chemotherapy instead of best supportive care should be carefully assessed in this setting, given its potential lack of benefit.
The retrospective design of this study did not allow us to report the adverse events related to chemotherapy and the impact of systemic therapy on the symptoms related to the disease. However, the review of the medical records indicated that the majority of the patients did not exhibit significant complications. Given the frequently high abdominal tumor burden of advanced WDLPS/DDLPS and its related symptoms, we believe that quality of life should be included as end point in the future clinical trials evaluating the role of new drugs in this specific setting.
One other aim of this study was to provide data that could be used as a reference for response and outcome in the assessment of investigational drugs in WDLPS/DDLPS. There is indeed an urgent need for improved therapeutics in WDLPS/DDLPS and the better understanding of their tumorigenesis has recently leaded to the development of several targeted antitumoral strategies. One strategy consists in targeting the oncogenes contained in the 12q13-15 amplicon and among them MDM2 and CDK4. For instance, in vitro data have shown that the MDM2 antagonist nutlin 3A can efficiently induce apoptosis in WDLPS/DDLPS cell lines [30] . Strikingly, preliminary data from a phase 0 study including 20 patients with WDLPS/DDLPS (http://clinicaltrials. gov/ct2/show/NCT01143740?term=RO5045337&rank=2) have shown that the MDM2 antagonist RG7112 (Hoffmann-La Roche, Penzberg, Germany) is able to increase the expression of p53 and p21 and decrease the expression of Ki-67 in human tumors. Early signs of clinical activity have also been observed but need further confirmatory studies [31] . CDK4 inhibitors are also currently under investigation in WDLPS/DDLPS (http://clinicaltrials.gov/ ct2/show/NCT01209598?term=cdk4&rank=5) but the amplification of this oncogene may represent only a secondary event in LPS tumorigenesis [32] . Another strategy may consist in 
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inducing the differentiation of DDLPS cells by interacting with the peroxisome proliferator-activated receptor-c (PPARc) [33] , with mixed results in early clinical trials [34] [35] [36] , or the c-Jun-NTerminal kinase (JNK) signaling pathway, highlighted more recently, with promising preclinical data [37] that need though to be confirmed in clinical trials. Moreover, recent works have also shown that WDLPS and DDLPS overexpress several tyrosine kinase receptors including EGFR, MET, AXL and IGF1R [38] . These preliminary but highly interesting data warrant further studies.
In conclusion, we report here the largest series to date of advanced WDLPS/DDLPS patients treated by chemotherapy. In this study, chemotherapy was largely dominated by anthracycline and, despite a low response rate, was associated with a clinical benefit in 45% of patients. Objective response rate was higher with combination chemotherapy but this had no impact on PFS and OS. Nevertheless, the results of conventional chemotherapy are not satisfying for patients with advanced WDLPS/DDLPS. Their PFS and OS remain poor, even if visceral metastatic disease is less frequent than in other sarcomas. Moreover, given the potential toxicity and the moderate benefit expected with standard chemotherapy, best supportive care should be considered in patients with poor PS.
The recent explosion of knowledge regarding the cytogenetic, molecular and cellular specificities of this group of tumors has lead to the development of new targeted therapies, such as MDM2 antagonists or CDK4 inhibitors, which are currently tested with great hopes to improve the clinical outcomes of patients suffering from advanced WDLPS/DDLPS. Our results should serve as a reference for response and outcome in the assessment of these investigational drugs.
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